Genprex inc GNPX.US 總覽分析
GNPX 投資分析
看多重點：
- 價值≥4
- 股利≥2
分析結論
價值面評分低，若以價值投資為目標且有長期投資部位，需要嚴格執行自己的出場計畫來減持部位
GNPX 近期報酬表現
-3.26%
Genprex inc
4.57%
同產業平均
3.26%
S&P500
與 GNPX 同產業的標的表現
- ALLK Allakos inc價值 3 分趨勢 3 分波段 2 分籌碼 3 分股利 1 分查看更多
GNPX 公司資訊
Genprex, Inc. is a clinical-stage gene therapy company focused on developing therapies for patients with cancer and diabetes. The Company's technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes, who have limited treatment options. Its oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid nanoparticles. The Company's lead product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Using a different gene therapy delivery system, the Company is also developing its preclinical diabetes candidate GPX-002 using the same construct for both Type 1 diabetes and Type 2 diabetes. It conducts preclinical research to explore how REQORSA may be administered in other solid tumors.